Abstract: The invention relates to a single-piece feeder body for use as a component of a two-part or multi-part telescopic feeder insert in metal casting, having a feeder wall which at least partially delimits a feeder cavity for receiving liquid metal, wherein the feeder wall has a passage opening for the liquid metal into the feeder cavity, and an outer surface on which there are arranged at least one outwardly projecting holding element and at least one guide part with a sliding section for a feeder element which corresponds with the feeder body, wherein the guide part has a supporting section which protrudes outwardly on the outer surface and which, adjoining the sliding section of the guide part for guiding the feeder element, extends in the direction of the passage opening.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(triflu-oromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl] [2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of car-diopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hyperten-sion (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pu

Abstract: The present invention relates to a novel and improved process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluo-romethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of the formula (I) and to novel crystalline forms of it, which is i.a. the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), furthermore the present invention relates to a novel and selective crystallization process for preparation of the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), preferably monohydrate I of formula (I-M-I) and to pharmaceutical compositions comprising monohydrate I of formula (I-M-I) and to its use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiopulmonary and cardiovascular diseases.

Abstract: The invention relates to a feeder insert (1, 1?, 1?, 1??, 100, 100?) for use in metal casting in casting molds, comprising a feeder body (2, 2?, 2?, 2??, 102, 102?) which delimits a feeder cavity (4, 4?, 4?, 4??, 104, 104?) for receiving liquid metal, wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) has a first end (6, 6?, 6?, 6??, 106, 106?) having a passage opening (8) for the liquid metal and a second end (10, 10?, 10?, 10??, 110, 110?) opposite the first end (6, 6?, 6?, 6??, 106, 106?), and wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) comprises a central axis (Z) extending through the passage opening (8). The feeder body (2, 2?, 2?, 2??, 102, 102?) is separated at least one partition plane (E) extending in a direction of the central axis (Z) and is formed at least from a first feeder shell (18, 18?, 18?, 18??, 118, 118?) and a second feeder shell (20, 20?, 20?, 20??, 120, 120?).

Abstract: The invention relates to a feeder insert (1, 1?, 1?, 1??, 100, 100?) for use in metal casting in casting molds, comprising a feeder body (2, 2?, 2?, 2??, 102, 102?) which delimits a feeder cavity (4, 4?, 4?, 4??, 104, 104?) for receiving liquid metal, wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) has a first end (6, 6?, 6?, 6??, 106, 106?) having a passage opening (8) for the liquid metal and a second end (10, 10?, 10?, 10??, 110, 110?) opposite the first end (6, 6?, 6?, 6??, 106, 106?), and wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) comprises a central axis (Z) extending through the passage opening (8). The feeder body (2, 2?, 2?, 2??, 102, 102?) is separated at least one partition plane (E) extending in a direction of the central axis (Z) and is formed at least from a first feeder shell (18, 18?, 18?, 18??, 118, 118?) and a second feeder shell (20, 20?, 20?, 20??, 120, 120?).

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmon

Abstract: The invention relates to a feeder insert (1, 1?) for use in the casting of metals in casting molds, with a feeder body (2, 2?) and a feeder element (4, 4?) which interacts with the feeder body (2, 2?), which delimit a feeder cavity (6) for receiving liquid metal, the feeder body (2, 2?) having a first end (8) with a passage opening (10) for the liquid metal, and a second end (12) which lies opposite the first end (8) and is open, and the feeder element (4, 4?) being arranged at this second, open end (12), it being possible for portions of the feeder body (2, 2?) and the feeder element (4, 4?) to be displaced telescopically inside one another, with the result that the feeder cavity (6) can be compressed down to a minimum volume VK, the feeder body (2, 2?) defining at least a proportion of 40% of this minimum volume VK.

Abstract: Chiral 3-sulfinylbenzoic acids of the respective absolute configuration given in formulae (I-R) and (I-S) are described as precursors for preparation of herbicidal compounds. In formulae (I-R) and (I-S). X. Z and R? represent radicals such as alkyl, cycloalkyl, haloalkyl and halogen.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmo

Abstract: The present invention relates to a novel process for preparing chlorobenzaldehyde oximes of the general formula (I).

Abstract: The invention relates to a feeder insert (1, 1?, 1?, 1??, 100, 100?) for use in metal casting in casting molds, comprising a feeder body (2, 2?, 2?, 2??, 102, 102?) which delimits a feeder cavity (4, 4?, 4?, 4??, 104, 104?) for receiving liquid metal, wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) has a first end (6, 6?, 6?, 6??, 106, 106?) having a passage opening (8) for the liquid metal and a second end (10, 10?, 10?, 10??, 110, 110) opposite the first end (6, 6?, 6?, 6??, 106, 106?), and wherein the feeder body (2, 2?, 2?, 2??, 102, 102?) comprises a central axis (Z) extending through the passage opening (8). The feeder body (2, 2?, 2?, 2??, 102, 102?) is separated at least one partition plane (E) extending in a direction of the central axis (Z) and is formed at least from a first feeder shell (18, 18?, 18?, 18??, 118, 118?) and a second feeder shell (20, 20?, 20?, 20??, 120, 120).

Abstract: The present invention relates to a novel and improved process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluo-romethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of the formula (I) and to novel crystalline forms of it, which is i.a. the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), furthermore the present invention relates to a novel and selective crystallization process for preparation of the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), preferably monohydrate I of formula (I-M-I) and to pharmaceutical compositions comprising monohydrate I of formula (I-M-I) and to its use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiopulmonary and cardiovascular diseases.

Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

Abstract: The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Abstract: The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Abstract: The invention relates to a single-piece feeder body for use as a component of a two-part or multi-part telescopic feeder insert in metal casting, having a feeder wall which at least partially delimits a feeder cavity for receiving liquid metal, wherein the feeder wall has a passage opening for the liquid metal into the feeder cavity, and an outer surface on which there are arranged at least one outwardly projecting holding element and at least one guide part with a sliding section for a feeder element which corresponds with the feeder body, wherein the guide part has a supporting section which protrudes outwardly on the outer surface and which, adjoining the sliding section of the guide part for guiding the feeder element, extends in the direction of the passage opening.

Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Abstract: The invention relates to a method for producing a mold part (26, 26?) with a feeder insert arranged in it, with a sprue for liquid metal, for a divisible casting mold for metal casting, with the following steps: producing or providing a mold part (26, 26?) equipped with a closed feeder insert (2, 2?) from a compacted molding material (28), the closed feeder insert (2, 2?) being arranged fixed in place in the compacted molding material (28) of the mold part (26, 26?) and having a feeder opening (10, 10?) connected to regions of the mold cavity (30, 30?) that is to be formed, and opening the closed feeder insert (2, 2?), so that a sprue (32, 32?) for liquid metal is formed.